Understanding and overcoming metformin gastrointestinal intolerance

Area of Science:

• Endocrinology
• Pharmacology
• Gastroenterology

Background:

• Metformin is the primary medication for type 2 diabetes mellitus (T2DM).
• A significant number of patients experience gastrointestinal (GI) adverse events (AEs), limiting metformin adherence and efficacy.
• Common GI AEs include diarrhea, nausea, flatulence, and abdominal discomfort.

Purpose of the Study:

• To review the epidemiology and mechanisms of metformin-associated GI intolerance.
• To explore factors influencing GI intolerance, including genetics, comorbidities, and co-medications.
• To discuss clinical consequences and therapeutic strategies for managing metformin GI intolerance.

Main Methods:

• Literature review of epidemiological data.
• Analysis of mechanisms underlying GI intolerance.
• Evaluation of therapeutic strategies and alternative treatments.

Main Results:

• Metformin-associated GI intolerance is common, impacting treatment adherence.
• Mechanisms of GI intolerance are not fully understood but influenced by various factors.
• Several strategies exist to mitigate GI AEs, including dose titration, extended-release formulations, and microbiome modulation.

Conclusions:

• Efforts should prioritize maintaining metformin therapy due to its clinical importance.
• Management strategies can improve patient tolerance to metformin.
• Further research into underlying mechanisms may yield novel therapeutic approaches.